MARIANNE

NCT01120184 📎

Regimen

Experimental
T-DM1 alone or T-DM1 + pertuzumab.
Control
Trastuzumab + taxane (standard 1L before CLEOPATRA became standard).

Population

HER2-positive progressive or recurrent locally advanced or previously untreated metastatic breast cancer.

Key finding

MARIANNE failed to show superiority of T-DM1 or T-DM1 + pertuzumab over trastuzumab + taxane in 1L. Cemented CLEOPATRA (pertuzumab + trastuzumab + docetaxel) as unchallenged 1L standard until DESTINY-Breast09.

Source: PMID 28056202

Timeline

  • Publication: 2017 Jan 10

Guideline citations

  • NCCN BREAST